Sun Pharmaceutical Industries has expanded its presence in the global oncology space with the launch of a new skin cancer treatment, Unloxcyt, in the United States. The introduction marks a strategic milestone for India’s largest drugmaker as it deepens its focus on specialty and complex therapies in regulated markets. The drug targets a specific segment of skin cancer patients and reflects Sun Pharma’s sustained investment in research, development, and regulatory approvals. Industry experts view the launch as a calculated move to strengthen the company’s U.S.